MAUREL, Marine, Jennifer HOWARD, Esther KISSLING, Francisco POZO, Gloria PEREZ-GIMENO, Silke BUDA, Noemie SEVE, Adele MCK-ENNA, Adam MEIJER, Ana Paula RODRIGUES, Ivan MARTINEZ-BAZ, Ivan MLINARIC, Neus LATORRE-MARGALEF, Gergo TURI, Mihaela LAZAR, Clara MAZAGATOS, Aitziber ECHEVERRIA, Stephen ABELA, Marc BOURGEOIS, Ausenda MACHADO, Ralf DUERRWALD, Goranka PETROVIC, Beatrix OROSZI, Ligita JANCORIENE, Alexandru MARIN, Petr HUSA, Roisin DUFFY, Frederika DIJKSTRA, Virtudes Gallardo GARCIA, Luise GOERLITZ, Vincent ENOUF, Charlene BENNETT, Mariette HOOIVELD, Raquel GUIOMAR, Camino TROBAJO-SANMARTIN, Vesna Visekruna VUCINA, Tove Samuelsson HAGEY, Ana Sofia Lameiras AZEVEDO, Jesus CASTILLA, Gerd XUEREB, Benedicte DELAERE, Veronica GOMEZ, Kristin TOLKSDORF, Sabrina BACCI, Nathalie NICOLAY, Marlena KACZMAREK and MC Rose ANGELA. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. EUROSURVEILLANCE. STOCKHOLM: EUR CENTRE DIS PREVENTION & CONTROL, 2024, vol. 29, No 8, p. 1-8. ISSN 1025-496X. Available from: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Authors MAUREL, Marine, Jennifer HOWARD, Esther KISSLING, Francisco POZO, Gloria PEREZ-GIMENO, Silke BUDA, Noemie SEVE, Adele MCK-ENNA, Adam MEIJER, Ana Paula RODRIGUES, Ivan MARTINEZ-BAZ, Ivan MLINARIC, Neus LATORRE-MARGALEF, Gergo TURI, Mihaela LAZAR, Clara MAZAGATOS, Aitziber ECHEVERRIA, Stephen ABELA, Marc BOURGEOIS, Ausenda MACHADO, Ralf DUERRWALD, Goranka PETROVIC, Beatrix OROSZI, Ligita JANCORIENE, Alexandru MARIN, Petr HUSA (203 Czech Republic, belonging to the institution), Roisin DUFFY, Frederika DIJKSTRA, Virtudes Gallardo GARCIA, Luise GOERLITZ, Vincent ENOUF, Charlene BENNETT, Mariette HOOIVELD, Raquel GUIOMAR, Camino TROBAJO-SANMARTIN, Vesna Visekruna VUCINA, Tove Samuelsson HAGEY, Ana Sofia Lameiras AZEVEDO, Jesus CASTILLA, Gerd XUEREB, Benedicte DELAERE, Veronica GOMEZ, Kristin TOLKSDORF, Sabrina BACCI, Nathalie NICOLAY, Marlena KACZMAREK and MC Rose ANGELA.
Edition EUROSURVEILLANCE, STOCKHOLM, EUR CENTRE DIS PREVENTION & CONTROL, 2024, 1025-496X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30303 Infectious Diseases
Country of publisher Sweden
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 19.000 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089
UT WoS 001198722300003
Keywords in English Influenza A vaccine effectiveness; European primary care; hospital multicentre studies
Tags 14110214, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 20/8/2024 13:39.
Abstract
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU -PC) and hospital (EU -H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU -PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU -H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
PrintDisplayed: 29/8/2024 02:20